Retrophin Inc (NASDAQ:RTRX) Shifting Institutional Investors Sentiment

June 17, 2018 - By Adrian Mccoy

Retrophin, Inc. (NASDAQ:RTRX) Logo

Sentiment for Retrophin Inc (NASDAQ:RTRX)

Retrophin Inc (NASDAQ:RTRX) institutional sentiment increased to 1.24 in Q1 2018. Its up 0.11, from 1.13 in 2017Q4. The ratio has improved, as 57 institutional investors started new and increased stock positions, while 46 sold and reduced their stock positions in Retrophin Inc. The institutional investors in our partner’s database reported: 39.72 million shares, up from 38.84 million shares in 2017Q4. Also, the number of institutional investors holding Retrophin Inc in their top 10 stock positions was flat from 2 to 2 for the same number . Sold All: 14 Reduced: 32 Increased: 36 New Position: 21.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. The company has market cap of $1.15 billion. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. It currently has negative earnings. The companyÂ’s product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.

The stock increased 3.30% or $0.92 during the last trading session, reaching $28.81. About 249,189 shares traded. Retrophin, Inc. (NASDAQ:RTRX) has risen 70.38% since June 17, 2017 and is uptrending. It has outperformed by 57.81% the S&P500.

Analysts await Retrophin, Inc. (NASDAQ:RTRX) to report earnings on August, 8. They expect $-0.40 earnings per share, down 17.65 % or $0.06 from last year’s $-0.34 per share. After $-0.46 actual earnings per share reported by Retrophin, Inc. for the previous quarter, Wall Street now forecasts -13.04 % EPS growth.

Consonance Capital Management Lp holds 7.55% of its portfolio in Retrophin, Inc. for 3.69 million shares. Broadfin Capital Llc owns 1.18 million shares or 4.11% of their US portfolio. Moreover, Perceptive Advisors Llc has 2.01% invested in the company for 3.21 million shares. The Georgia-based Emory University has invested 1.84% in the stock. Ghost Tree Capital Llc, a New York-based fund reported 314,367 shares.

Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $44,878 activity.

More notable recent Retrophin, Inc. (NASDAQ:RTRX) news were published by: Nasdaq.com which released: “Research Report Identifies Corbus Pharmaceuticals, Retrophin, Charter Financial, HighPoint Resources, Southern …” on June 06, 2018, also Nasdaq.com with their article: “Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued US Patent” published on June 14, 2018, Globenewswire.com published: “Retrophin to Present at Upcoming Investor Conferences” on May 24, 2018. More interesting news about Retrophin, Inc. (NASDAQ:RTRX) were released by: Streetinsider.com and their article: “Retrophin (RTRX) Secures New Patent for Product Candidate Sparsentan” published on June 14, 2018 as well as Nasdaq.com‘s news article titled: “Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric …” with publication date: June 04, 2018.

Retrophin, Inc. (NASDAQ:RTRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: